Newcastle Gateshead Clinical Commisioning Group
In January 2016, following the merger of Newcastle North and East, Newcastle West and Gateshead CCGs, the North of Tyne Area Prescribing Committee merged with Gateshead Medicines Management Committee.
The North of Tyne & Gateshead Area Prescribing Committee is responsible for clinical decision making and advice in relation to prescribing and medicines optimisation.The Area Prescribing Committee (APC) serves the following participating organisations:
- Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH)
- Northumberland, Tyne and Wear NHS Foundation Trust (NTWT)
- Northumbria Healthcare NHS Foundation Trust (NHCT)
- NHS Northumberland Clinical Commissioning Group
- NHS North Tyneside Clinical Commissioning Group
- NHS Newcastle Gateshead CCG
- Gateshead Health NHS Foundation Trust
New Drugs Policy
The North of Tyne & Gateshead Area Prescribing Committee is responsible for approval of new drugs and extending the use of existing formulary drugs to new indications and for the production of the North of Tyne and Gateshead formulary which provide details of medicines approved for use in Newcastle and Gateshead. Decisions around new drug requests take into consideration safety, clinical effectiveness, and cost-effectiveness relative to other treatment options for the condition under discussion, as well as the potential available budget. Decisions will be made on fully published trial data only.
The North of Tyne & Gateshead formulary replaces the former Gateshead formulary and North of Tyne formulary. It is available to browse online at the following link:
Prescribing guidelines for Newcastle Gateshead CCG are published on the North of England Commissioning Support Medicines Optimisation website. Work is underway to consolidate existing guidelines that cover Newcastle and Gateshead but in the interim period prescribers should use guidance relevant to their locality, where a joint guideline does not exist.
Medicines with a positive NICE Technology Appraisal will be automatically added to the local formulary. This process should take place within 3 months of the date of publication of the NICE Technology Appraisal. Where NICE states ‘option for treatment’, the medicine will be added to the local formulary and if necessary its place in the relevant local care pathway(s) be defined or if it is not the preferred option in the current pathway, the medicine will appear in the formulary with the following note “not a preferred option in the current pathway but is available on individual patient basis as per NICE Technology Appraisal”.
The CCG’s position with regards to commissioning of drugs endorsed through the NICE technology Appraisal process can be found here
Decision summaries and minutes of the North of Tyne & Gateshead APC meetings